Oncology News

Liver resection was safe among patients with metabolic syndrome- and hepatitis C virus-related hepatocellular carcinoma, with only cirrhosis associated with worse short-term outcomes, according to study data.

Transarterial ethanol-lipiodol embolization was a safer and more effective technique for treating patients with hepatocellular carcinoma compared with conventional transarterial chemoembolization, according to study findings.

Radiation therapy using yttrium-90 resin microspheres combined with chemotherapy did not improve overall progression-free survival in patients with nonresectable metastatic colorectal cancer. However, the combination regimen did improve survival in patients with liver-only metastases, according to newly published data on the SIRFLOX study.

The French National Agency for Medicines and Health Products has given Nanobiotix authorization to begin a clinical trial investigating its drug NBTXR3 for the treatment of liver metastasis and hepatocellular carcinoma, according to a press release.

Provectus Biopharmaceuticals, Inc. announced it has signed a Letter of Intent with Boehringer Ingelheim Investment Co. Ltd. in China to collaborate in marketing its potential liver cancer and melanoma drug, PV-10, in mainland China, Hong Kong and Taiwan, according to a press release.

Researchers in Korea used transient elastography and found it to be useful in identifying subclinical cirrhosis among patients at risk for hepatitis B virus infection-related hepatocellular carcinoma who did not have evidence of cirrhosis, according to study data.

CHICAGO — Patients with hepatitis B virus infection were more likely to develop hepatocellular carcinoma at a younger age and have a more aggressive form of the disease vs. patients with hepatitis C virus infection, according to study results presented at the ASCO Annual Meeting.

Patients who underwent successful downstaging for hepatocellular carcinoma had a lower chance of recurrence and higher chance of survival post-liver transplant vs. patients without downstaging, according to study data.

Phase 3 results from the REACH study showed that Cyramza therapy did not significantly improve survival more than placebo in patients with advanced hepatocellular carcinoma after treatment with sorafenib, according to new data published in The Lancet Oncology.

Researchers suggest that interferon L3 rs12979860 may be a risk factor for the development of hepatocellular carcinoma among patients treated for hepatitis C virus infection, according to published data from a retrospective study.